Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

OBJECTIVE: Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti‐Aβ antibodies are capable of lowering oAβ levels in humans. METHODS: We developed an ultrasensitive immunoassay and used it...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Neurol
Asıl Yazarlar: Yang, Ting, Dang, Yifan, Ostaszewski, Beth, Mengel, David, Steffen, Verena, Rabe, Christina, Bittner, Tobias, Walsh, Dominic M., Selkoe, Dennis J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2019
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771589/
https://ncbi.nlm.nih.gov/pubmed/31168802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25513
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller